The evaluation of Probiotic lactocare effect on immune responses and clinical manifestation in patients with parennial allergic rhinitis

Probiotic prescribing on immune responses and clinical manifestations in patients with parennial allergic rhinitis

Pragmatic, community based, parallel group, double blind, randomised controlled trial

Before and 6 months after the intervention, Brachial vein of 5cc patients is taken to perform flow cytometric studies and serum preparation for the sample bank. Also, the miniRQLQ and SNOT22 questionnaires, which are related to quality of life and severity of the disease, are completed before and after the intervention by the patients.

Inclusion Criteria: All patients with parennial allergic rhinitis aged 5 to 5 years old living in Mashhad and surrounding cities who have positive skin tests with aeroallergen and who are required to collaborate. exclusion criteria: Patients with a history of autoimmune disease, patients who have systemic corticosteroids or immunosuppressive drugs that are effective on the immune system, pregnant women, immunocompromised patients, patients with allergic asthma,Malnutrition patients, and patients Antibiotics are used for any reason during the use of the probiotic.

Patients are divided into two equal groups (in each group of 15) using a randomized block method. In addition to common allergic rhinitis treatments, lactocare is prescribed and in the other group, in addition to the usual treatments, placebo is prescribed.

The level of IL25 proteins affects the frequency of Th1, Th2, Th17, and Treg cells, as well as the expression of T-bet, GATA3, RORgamma t and FOXP3 transcription factor gene expression at the start of the process, six months after the course.

Method of block randomization Unit of randomization individual Tools used in randomization computer softwares

Participants will receive the same drug or placebo The main researcher is unaware of the effect of the drug on improving quality of life and effective immune responses.